<DOC>
	<DOCNO>NCT00485979</DOCNO>
	<brief_summary>The primary objective study assess pathological Complete Response ( pCR ) rate treatment arm ( accord Chevallier criterion ) . The secondary objective : - ass treatment arm clinical Response Rate ( RR ) , rate breast conservation , Progression-Free Survival ( PFS ) , Overall Survival ( OS ) , safety tolerability profile , pathological Complete Response rate ( pCR ) accord NSABP Sataloff criterion , - rank docetaxel larotaxel alone Her2 -ve patient , combine trastuzumab Her2 +ve patient , accord pCR rate .</brief_summary>
	<brief_title>Treatment Larotaxel/Docetaxel , +/- Trastuzumab , After Anthracycline-cyclophosphamide Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically proven invasive breast adenocarcinoma Localized breast cancer : stage II III Tumors clinically palpable ineligible breast conservative surgery : unifocal tumor diameter â‰¥ 3cm ( clinical examination ) central unifocal tumor , whose characteristic make preoperative chemotherapy mandatory due high risk factor ( i.e . ipsilateral lymph node involvement , rapid growth rate ) After 30 June 2008 , know status Her2neu immunohistochemistry ( IHC ) fluorescent situ hybridization ( FISH ) Bilateral inflammatory breast cancer Abnormal Left Ventricular Ejection Fraction Distant metastases locoregional relapse Inadequate organ function The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Neoadjuvant therapy</keyword>
</DOC>